Switch Case Study: GSK Alli Review Shows FDA Data Mining In Context
This article was originally published in The Tan Sheet
[F-D-C Reports' Pharmaceutical Approvals Monthly dissects drug reviews by FDA. While each drug stands or fails alone, a specific review can provide valuable insight into FDA's interpretation of data, policy and guidance documents, recurring controversies and resolution of internal disagreement. This story completes a two-part feature on alli.
You may also be interested in...
When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice
FDA is implementing the Safety First initiative to "ensure that significant post-market safety issues are our highest priority," according to acting Center for Drug Evaluation and Research Director Janet Woodcock
FDA's approved labeling for GlaxoSmithKline's first-in-class nonprescription weight-loss drug alli (orlistat 60 mg) emphasizes a "goal oriented" indication as opposed to a six-month duration of use as originally proposed